Presentation is loading. Please wait.

Presentation is loading. Please wait.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Published byMay Davis Modified over 9 years ago

Similar presentations

Presentation on theme: "Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee."— Presentation transcript:

1 Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee 28 February 2007

2 Serum panels used for serology AUSTRALIA IAN BARR, PH.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1) WHO, AUSTRALIA ELDERLY A/NEW YORK/55/04 (H3N2) B/MALAYSIA/2506/05 EUROPE JOHN WOOD, PH.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1) NIBSC, ENGLAND ELDERLY A/WISCONSIN/67/05 (H3N2) or A/HIROSHIMA/52/2006 (H3N2) B/MALAYSIA/2506/05 JAPAN TAKATO ODIGARI, PH.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1) NIID, JAPAN ELDERLY A/HIROSHIMA/52/2006 (H3N2) B/MALAYSIA/2506/05 USA STEFAN GRAVENSTEIN, M.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1) EASTERN VIRGINIA ELDERLY A/WISCONSIN/67/05 (H3N2) MEDICAL SCHOOL, PEDIATRIC B/MALAYSIA/2506/05 1

3 Antigens for serology (H1N1) VACCINE STRAIN A/New Caledonia/20/99 IVR116 REPRESENTATIVE CURRENT STRAINS l A/England/555/2006 l A/Fukushima/141/2006 l A/Guangxigangbei/322/2006 l A/St. Petersburg/8/2006 l A/Hong Kong/2652/2006* l A/Norway/2289/2006* l A/Solomon Islands/3/2006* * K144E Change Present 2

4 HI ANTIBODY RESPONSES TO THE H1N1 ADULT POPULATION (UK) TrialVirus strainPre- vacc % HI>40 Post- vacc % HI>40 % rise pre- vacc GMT Post- vacc GMT Adult EU –W 24A/New Caledonia/20/9921887510190 A/England/555/2006046 636 A/Fukushima/141/06063 5 A/Norway/2289/2006 *(K114E) 06358661 A/Solomon Islands/3/06 *(K114E) 1367639133 A/St. Petersburg/8/0647571690 A/Virginia/1/20061375678122 Adult Australi a 24A/New Caledonia/20/9971962188192 A/England/555/20064671172342 A/Fukushima/141/066379173991 A/Norway/2289/2006 *(K114E) 3358171838 A/Solomon Islands/3/06 *(K114E) 718385291 A/St. Petersburg/8/064271172448 A/Virginia/1/20065488174177 3

5 HI ANTIBODY RESPONSES TO THE H1N1 ADULT POPULATION (UK) TrialNo. of Sera Virus strainPre- vacc % HI>40 Post- vacc % HI>40 % rise pre- vacc GMT Post- vacc GMT Adult USA 24A/New Caledonia/20/99711003889273 A/England/555/20063363251340 A/Fukushima/141/065471212458 A/Norway/2289/2006 *(K114E) 2963251432 A/Solomon Islands/3/06 *(K114E) 50832538105 A/St. Petersburg/8/063371382161 A/Virginia/1/200650925035130 Adult Japan 30A/New Caledonia/20/993380271959 A/England/555/2006132717922 A/Fukushima/141/061337171026 A/Norway/2289/2006 *(K114E) 32317716 A/Solomon Islands/3/06 *(K114E) 1053331030 A/St. Petersburg/8/061037209 A/Virginia/1/2006508727 74 4

6 A/New Caledonia/20/99 VACCINES SUMMARY TABLE VIRUSES WITH > 50% GMT REDUCTION ( ADULT) 5

7 Antigens for serology (H3N2) VACCINE STRAIN A/Wisconsin/67/2005 X161B A/Hiroshima/52/2006 IVR-142 REPRESENTATIVE CURRENT STRAINS l A/Brisbane/9/2006 l A/Hiroshima/33/2005 l A/Norway/2250/2006 l A/Sendai-H/F131/2006 l A/Santiago/7981/2006 l A/Canada/1212/2006* l A/Lyon/1292/2006* *Canada/Nepal Genetic Group 6

8 HI ANTIBODY RESPONSES TO THE H3N2 ADULT POPULATION (CDC) TrialNAntigen % Rise Pre- vacc GMT Post- vacc GMT Pre- vacc % HI>40 Post- vacc % HI>40 Australia24A/Wisconsin/67/200571151012596 24A/Brisbane/9/20066715652179 24A/Santiago/7981/200646822838 23A/Canada/1212/2006*481449 23A/Hiroshima/33/200642714822 UK24A/Wisconsin/67/20057991511388 24A/Brisbane/9/200675792483 24A/Santiago/7981/200650618442 24A/Canada/1212/2006 *38614425 24A/Hiroshima/33/200642515433 7

9 HI ANTIBODY RESPONSES TO THE H3N2 ADULT POPULATION (CDC) PopulationNAntigen % Rise Pre- vacc GMT Post- vacc GMT Pre- vacc % HI>40 Post- vacc % HI>40 Japan30A/Wisconsin/67/20054022674070 30A/Brisbane/9/20063316393053 30A/Santiago/7981/200613610320 30A/Canada/1212/2006 *23917727 28A/Hiroshima/33/200621610021 USA24A/Wisconsin/67/2005831412033100 24A/Brisbane/9/20067913782188 24A/Santiago/7981/200650723438 24A/Canada/1212/2006 *67519025 24A/Hiroshima/33/200646923433 8

10 A/Wisconsin/67/2005-like VACCINES SUMMARY TABLE VIRUSES WITH > 50% GMT REDUCTION ( ADULT) 9

11 Antigens for serology (B) VACCINE STRAIN B/Malaysia/2506/2004 ( B/Victora/2/87-HA lineage) REPRESENTATIVE CURRENT STRAINS l B/Bangladesh/5278/2006 l B/Texas/39/2006 l B/Chongqing-Y/131/2006 l B/Madagascar/2866/2006 l B/Michigan/2/2006* l B/Taiwan/79/2006* l B/Florida/4/2006* l B/Egypt/144/2005* * B/Yamagata/16/88-HA lineage 10

12 HI ANTIBODY RESPONSES TO B ADULT POPULATION (CDC) NAntigen % Rise Pre- vacc GMT Post- vacc GMT Pre- vacc % HI>40 Post- vacc % HI>40 UK24B/Malaysia/2506/200483869879 24B/Ohio/1/200589111262191 24B/Chongqing/Yz131/2006838641371 19B/Texas/39/200683760967 23B/Florida/4/2006*5812441771 23B/Michigan/2/2006*6310421767 Japan30B/Malaysia/2506/20042320524077 30B/Ohio/1/20052032785780 30B/Chongqing/Yz131/20062717443367 30B/Texas/39/20062319443770 30B/Florida/4/2006*712191733 30B/Michigan/2/2006*711141327 USA24B/Malaysia/2506/200471211473896 23B/Ohio/1/200565221514691 24B/Chongqing/Yz131/200667191273392 22B/Texas/39/200659231134188 24B/Florida/4/2006*38361166388 24B/Michigan/2/2006*46481606792 11

13 B/Malaysia/2560/2004 VACCINES SUMMARY TABLE VIRUSES WITH > 50% GMT REDUCTION ( ADULT) 12

14 Serologic conclusions Studies with sera collected after immunization with current vaccines show that: l H1 – Recent viruses not well inhibited compared to the current vaccine strain l H3 – Recent viruses not well inhibited compared to the current vaccine strain l B – Recent B/Vic lineage viruses generally well inhibited compared to the current vaccine strain 13

Download ppt "Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee."

Similar presentations

Duration of Serum Antibody Response to Seasonal Influenza Vaccines: Summary The level of antibody response made to seasonal influenza vaccines depends.

Duration of Serum Antibody Response to Seasonal Influenza Vaccines: Summary The level of antibody response made to seasonal influenza vaccines depends.
Candidate Vaccine Strains and Potency Reagents, 2009-2010 Season Rajesh K. Gupta, Ph.D. Deputy Director, Division of Product Quality OVRR, CBER, FDA Prepared.

Candidate Vaccine Strains and Potency Reagents, Season Rajesh K. Gupta, Ph.D. Deputy Director, Division of Product Quality OVRR, CBER, FDA Prepared.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
WORKING GROUP 1 Influenza Virulence and Antigenic Change Chairperson – Robert Webster Briefer – Peter Palese Rapporteur – Robert Lamb.

WORKING GROUP 1 Influenza Virulence and Antigenic Change Chairperson – Robert Webster Briefer – Peter Palese Rapporteur – Robert Lamb.
Influenza Surveillance

Influenza Surveillance
INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA (Seasonal Influenza and Zoonotic Influenza) FEBRUARY 28, 2012.

INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA (Seasonal Influenza and Zoonotic Influenza) FEBRUARY 28, 2012.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.

Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
U.S. Surveillance Update Anthony Fiore, MD, MPH CAPT, USPHS Influenza Division National Center for Immunizations and Respiratory Disease Centers for Disease.

U.S. Surveillance Update Anthony Fiore, MD, MPH CAPT, USPHS Influenza Division National Center for Immunizations and Respiratory Disease Centers for Disease.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.
Influenza Virus Vaccine 2013-2014 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.
Influenza Virus Vaccine 2014-2015 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.
Influenza Vaccine Manufacturing Industry perspective for 2012-2013 influenza vaccine supply VRBPAC, 28 February 2012 The FDA CBER requested this annual.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 28 February 2012 The FDA CBER requested this annual.
INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA FEBRUARY 22, 2010 Nancy J. Cox, Ph. D Director WHO COLLABORATING.

INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA FEBRUARY 22, 2010 Nancy J. Cox, Ph. D Director WHO COLLABORATING.
Influenza Virus Vaccine 2011-2012 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.
Vaccines and Related Biological Products Advisory Committee Presentation on Sanofi Pasteur’s H5N1 Vaccine Andrea N. James, M.D. Senior Medical Officer.

Vaccines and Related Biological Products Advisory Committee Presentation on Sanofi Pasteur’s H5N1 Vaccine Andrea N. James, M.D. Senior Medical Officer.

Similar presentations

Ads by Google